Abstract
The care of thoracic transplant patients centers on the use of immunosuppression to balance rejection (Chapters 8-10) against infection (Chapter 11), and on the management of these two major complications when the balance achieved is uneven. Primary care delivery to these patients is accomplished in the context of the unique toxicities and drug interactions of the immunosuppressive agents used (Chapters 8 and 10). Although some management issues directly relate to surgically altered anatomy, most are the consequence of the drugs that permit the coexistence of self with non-self.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bexton RS, Nathan AW, Hellestrand KJ et al. Sinoatrial function after cardiac transplantation. J Am Coll Cardiol. 1984;3:712.
Bexton RS, Nathan AW, Hellestrand KJ et al. Electrophysiological abnormalities in the transplanted human heart. Br Heart J. 1983;50:555.
Heinz G, Ohner T, Laufer G, Gasic S, Laczkovics A. Clinical and electrophysiologic correlates of sinus node dysfunction after orthotopic heart transplantation. Chest. 1990;97:890.
Miyamoto Y, Curtiss El, Kormos RL et al. Bradyarrhythmia after heart transplantation. Incidence, time course, and outcome. Circulation. 1990;82:313.
Scoll CD, Omar IR, McComb JM, Dark JH, Bexton RS. Long-term pacing in heart transplant recipients is usually unnecessary. Pace. 1991;14:1792.
Cooper MM, Smith CR, Rose EA, Schneller SJ, Spotnilz HM. Permanent pacing following cardiac transplantation. J Thorac Cardiovasc Surg. 1992;104:812.
Redmond JM, Zehr KJ, Gillinov MA et al. Use of theophylline for treatment of prolonged sinus node dysfunction in human orthotopic heart transplantation. J Heart Lung Transplant. 1993;12:133.
Cook LS, Will KR, Moran J. Treatment of junctional rhythm after heart transplantation with terbutaline. J Heart Transplant. 1989;8:342.
Macdonald P, Hackworthy R, Keogh A et al. Atrial overdrive pacing for reversion of atrial flutter after heart transplantation. J Heart Lung Transplant. 1991;10:731.
Scott CD, Dark JM, McComb JM. Arrhythmias after cardiac transplantation. Am J Cardiol. 1992;70:1061.
Vandenberg BF, Mohanty PK, Craddock KJ et al. Clinical significance of pericardial effusion after heart transplantation. J Heart Transplant. 1988;7:128.
Valantine HA, Hunt SA, Gibbons R et al. Increasing pericardial effusion in cardiac transplant recipients. Circulation. 1989;79:603.
Goldstein JA, Janu P, Fields B. Rectus femoris flap repair of recalcitrant inguinal lymphoceles after heart transplantation. J Heart Lung Transplant. 1994;13:549.
Mathes SJ, Nahia F. Sartorius muscle flap applications: coverage of groin femoral vessels and knee region. In: ?, editor. Clinical atlas of muscle and musculocutaneous flaps. St Louis, MO: Mosby: 1979:33.
Ragni T, Martinelli L, Goggi C et al. Echo-controlled endomyocardial biopsy. J Heart Transplant. 1990;9:538.
Baraldi-Junkins C, Levin HR, Kasper EK et al. Complications of endomyocardial biopsy in heart transplant patients. J Heart Lung Transplant. 1993;12:63.
Canedo MI. Comments on ‘complications of endomyocardial biopsy in heart trans plant patients’ (Letter). J Heart Lung Transplant. 1993;12:887.
Sutsch G, Heywood T, Turina J et al. Coronary artery-right ventricular fistula in a heart transplant patient. J Heart Transplant. 1990;9:32.
Sandhu JS, Uretsky BF, Zerbe TR et al. Coronary artery fistula in the heart transplant patient. A potential complication of endomyocardial biopsy. Circulation 1989;79:350.
Fitchett DH, Forbes C, Guerraty AJ. Repeated endomyocardial biopsy causing coronary arterial-right ventricular fistula after cardiac transplantation. Am J Cardiol. 1988;62:829.
Henzlova MJ, Nath H, Bucy RP et al. Coronary artery to right ventricle fistula in heart transplant recipients: a complication ot endomyocardial biopsy. J Am Coll Cardiol. 1989;14:258.
Schafers HJ, Wahlers I, Borst HG. Left ventricular function, tricuspid incompetence, and incidence of coronary artery disease late after orthotopic heart transplantation. Eur J Cardiothorac Surg. 1989;3:111.
Rees AP, Milani RV, Lavie CJ, Smart FW, Ventura HO. Valvular regurgitation and right-sided cardiac pressures in heart transplant recipients by complete Doppler and color flow evaluation. Chest. 1993;104:82.
Lewen MK, Bryg RJ, Miller LW, Williams GA, Labovitz AJ. Tricuspid regurgitation by Doppler echocardiography after orthotopic cardiac transplantation. Am J Cardiol. 1987;59:1371.
Credle WF, Smiddy JF, Elliott RC. Complications of fiberoptic bronchoscopy. Am Rev Respir Dis. 1974;109:67.
Herf SM, Suratt PM, Arora NS. Deaths and complications associated with transbronchial lung biopsy. Am Rev Respir Dis. 1977;115:708.
Pereira W, Kovnat DM, Snider GL. A prospective cooperative study of complications following flexible fiberoptic bronchoscopy. Chest. 1978;73:813.
Herf SM, Suratt PM. Complications of transbronchial lung biopsies. Chest. 1978;73:759.
Trulock HP, Ettinger NA, Brunt EM et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. Chest. 1992;102:1049.
Fulkerson WJ. Fiberoptic bronchoscopy. N Engl J Med. 1984;311:511.
Scott JP, Fradet G, Smyth RL et al. Prospective study of transbronchial biopsies in the management of heart-lung and single lung transplant patients. J Heart Lung Transplant. 1991;10:626.
Lorber Ml. Cyclosporine: lessons learned — future strategies. Clin Transplant. 1991;5:505.
Humes HO, Jackson NM, O’Connor RP et al. Pathogenetic mechanisms of nephrotoxicity: insight into cyclosporin nephrotoxicity. Transplant Proc. 1985;17:51.
Scott JP, Nuncz D, Hay IFC et al. Exercise-induced hypertension in normotensive renal transplant recipients receiving cyclosporin A. Transplant Proc. 1987;19:4002.
English J, Evan A, Houghton DC et al. Cyclosporine-induced acute renal dysfunction in the rat: evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 1987;44:135.
Jackson NM, Hsu CH, Visscher GE et al. Alterations in renal structure and function in a rat model of cyclosporin toxicity. J Pharmacol Exp Ther. 1987;242:749.
Myers BD, Newton L, Boshkos C et al. Chronic injury of human renal microves-sels with low-dose cyclosporin therapy. Transplantation. 1988;46:694.
Mason J. The pathophysiology of Sundimmune (cyclosporin) in men and animals. Pediatr Nephrol. 1990;4:554.
Myers BD, Ross J, Newton L et al. Cyclosporin associated chronic nephropathy. N Engl J Med. 1984;311:699.
Greeberg A, Thompson ME, Griffith BP et al. Cyclosporine nephrotoxicity in cardiac allograft patients — a seven year follow-up. Transplantation. 1990;50:589.
Zaltzman JS, Pey Y, Maurer J et al. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation. 1992;54:875.
Lewis RM, Van Buren CT, Radovancevic B et al. Impact of long-term cyclosporin immunosuppressive therapy on native kidneys vs renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant. 1991;10:63.
Waser M, Maggiorini M, Binswanger U et al. Irreversibility of cyclosporin-induced renal function impairment in heart transplant recipients. J Heart Lung Transplant. 1993;12:846.
Burke JP Jr, Pirsch JD, Ramos EL et al. Long-term efficacy and safety of cyclosporin in renal transplant recipients. N Engl J Med. 1994;331:358.
Almond PS, Gillingham KJ, Sibley R et al. Renal transplant function after cyclosporin. Transplantation. 1992;53:316.
Van Der Heide JJH, Bilo HJG, Donker JM et al. Effect of dietary fish oil on renal function and rejection in cyclosporin-treated recipients of renal transplants. N Engl J Med. 1993;329:769.
Markewitz A, Hammer C, Pfeiffer M et al. Reduction of cyclosporin-induced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation. 1994;57:865.
Moran M, Mozes MF, Maddux MS et al. Prevention of acute graft rejection by the prostaglandin E-I analogue misoprostol in renal transplant recipients treated with cyclosporin and prednisone. N Engl J Med. 1990;322:1183.
Adams MB and the Enisoprost Renal Study Group. Enisoprost in renal transplantation. Transplantation. 1992;53:338.
Wilke ME, Beer JC, Newman D et al. Evidence that the risks of Misoprostol outweigh its benefits in stable cyclosporin-treated renal allograft recipients. Transplantation. 1992;54:565.
Bianco JA, Almgren J, Kern DL et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporin. Transplantation. 1991;5l:925.
Bennett WM, Elzinga LW, Porter GA et al. The effects of pentoxifylline on experimental chronic cyclosporin nephrotoxicity. Transplantation. 1992;54:1118.
Tomlanovich S, Golbetz H, Perlroth M et al. Limitations of creatinine and quantifying the severity of cyclosporin-induced chronic nephropathy. Am J Kidney Dis. 1986;8:332.
Germain MJ, Lipkowitz GS, Guarnera J et al. A comparison of different methods of estimating glomerular filtration rate in cyclosporin-treated renal transplant patients. Transplantation. 1993;55:203.
Lewis R, Kerr N, Van Buren C et al. Comparative evaluation of urographic contrast media, inulin, and 99mTc-DTPA clearance methods for determination of glomerular filtration rate in clinical transplantation. Transplantation. 1989;48:790.
Jarowenko M, Flechner SM, Van Buren CT, Lorber MI, Kahan BD. Influence of cyclosporin on posttransplant blood pressure response. Am J Kidney Dis. 1987;10:98.
Lasko D, Curtis JJ. Post-transplant hypertension. Am J Hypertens. 1990;3:721.
Olivari MT, Antolick A, Ring WS. Arterial hypertension in heart transplant recipients treated with triple-drug immunosuppressive therapy. J Heart Transplant. 1989;8:34.
Scherrer U, Vissing SF, Morgan BJ et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation, N Engl J Med. 1990;323:693.
Valentine H, Keogh A, McIntosh N et al. Cost containment: co-administration of diltiazem with cyclosporin after heart transplantation. J Heart Lung Transplant. 1992;11:1.
Bunkey M, Ganzel B. Effective calcium channel antagonisms on renal function in hypertensive heart transplant recipients. J Heart Lung Transplant. 1992;11:1194.
Bennett WM, Myer MM. Considerations in the medical management of hypertension and cyclosporin A treated allograft recipients (Letter). Transpl. Immunol. 1992;8:4.
Angerman CE, Spes CH, Willems S et al. Circadian behavior of blood pressure and heart rate following orthotopic heart transplantation. Studies before and during antihypertensive therapy. Z Kardiol. 1989;78:228.
Dunn DH, Hoffman FM, General surgical diseases after cardiopulmonary transplantation. Cardiac Surg State Art Rev. 1989;3:653.
Villar HV, Neal DD, Levinson M et al. Gastrointestinal complications after human transplantation and mechanical heart replacement. Am J Surg. 1989;157:168.
Jones MT, Menkis AH, Kostuk WJ, McKenzic FN. Management of general surgical problems after cardiac transplantation. Can J Surg. 1988;31:259.
Disesa VJ, Kirkman RL, Tilney NL et al. Management of general surgical complications following cardiac transplantation. Arch Surg. 1989;124:539.
Aziz S, Bergdahl L, Baldwin JC et al. Pancreatitis after cardiac and cardiopulmonary transplantation. Surgery. 1985;97:653.
Sleek TB, Durkin MG, Costanzo-Nordin MR, Keshavarzian A. Gastrointestinal complications and endoscopic findings in heart transplant patients. J Heart Lung Transplant. 1993;12:244.
Merrell SW, Ames SW, Nelson EW et al. Major abdominal complications following cardiac transplantation. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program. Arch Surg. 1989;124:889.
Smith PC, Slaughter MS, Petty MG et al. Abdominal complications after lung transplantation. J Heart Lung Transplant. 1995;14:44.
Kaplan CS, Petersen EA, Icenogle TB et al. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients. Arch Intern Med. 1989;149:2095.
Merigan TC, Renlund DG, Keay S et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182.
Buckner FS, Pomeroy C. Cytomegalovirus disease of the gastrointestinal tract in patients without AIDS. Clin Infec Dis. 1993;17:644.
Van Thiel D, Gavaler JS, Schade RR, Chien MC, Starzl TE. Cytomegalovirus infection and gastric emptying. Transplantation. 1992;54:70.
Franzin G, Muolo A, Griminelli T. Cytomegalovirus inclusions in the gastroduodenal mucosa of patients after renal transplantation. Gut. 1981;22:698.
Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med. 1993;328:349.
Teenan RP, Burgoyne M, Brown IL, Murray WE. Helirobacter pylori in renal transplant recipients. Transplantation. 1993;56:100.
Parsonnet J, Hansen S, Rodriguez L et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267.
Mosimann F. Esophageal candidiasis, omeprazole therapy, and organ transplantation — a word of caution (Letter). Transplantation. 1993;56:492.
Steck TB, Costanzo-Nordin MR, Keshavarzian A. Prevalence and management of cholelithiasis in heart transplant patients. J Heart Lung Transplant. 1991;10:1029.
Peterseim DS, Chesnut LC, Meyers CH et al. Stability of the beta-adrenergie receptor/adenyl cyclase pathway of pediatric myocardium after brain death. J Heart Lung Transplant. 1994;13:635.
Sharobeem R, Bacq Y, Furet Y et al. Cyclosporine A and ursodeoxycholic acid interaction. Clin Trans. 1993;7:223.
Adiseshiah M, Wells FC, Cory-Pearce R, Wallwork J, English TA. Acute pancreatitis after cardiac transplantation. World J Surg. 1983;7:519.
Fernandez JA, Rosenberg JC. Post-transplantation pancreatitis. Surg. Gynecol. Obstet. 1976;143:795.
Mallory A, Kern F. Drug-induced pancreatitis: a critical review. Gastroenterology. 1980;78:813.
Fernandez-Del Castillo C, Harringer W, Warshaw AL et al. Risk factors for pancreatic cellular injury after cardiopulmonary bypass. N Engl J Med 1991;325:382.
Taft PM, Jones AC, Collins GM, Halasz NA. Acute pancreatitis following renal allotransplantation. A lethal complication. Am J Dig Dis. 1978;23:541.
Johnson WC, Nabseth DC. Pancreatitis in renal transplantation. Ann Surg. 1970;171:309.
Williams G, Kyriakidis A, Gastro JE. Pancreatitis complicating renal transplantation. J R Coll Surg Edin. 1981;26, 184.
Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994;330:1198.
Church JM, Fazio VW, Braun WE, Novick AC, Steinmuller DR. Perforation of the colon in renal homograft recipients, A report of 11 cases and a review of the literature. Ann Surg. 1986;203:69.
Squiers EC, Pfaff WW, Patton PR, Howard RJ. Early posttransplant colon perforation: does it remain a problem in the cyclosporin era? Transplant Proc. 1991;23:1782.
Koneru B, Selby R, O’Hair DP et al. Nonobstructing colonic dilatation and colon perforations following renal transplantation. Arch Surg. 1990;125:610.
Ballantyne CM, Jones PH, Payton-Ross C et al. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987;19:60.
Taylor DO, Thompson JA, Hastillo A et al. Hyperlipidemia after clinical heart transplantation. J Heart Transplant. 1989;8:209.
Ballantyne CM, Radovancevie B, Farmer JA et al. Hyperlipidemia after heart transplantation: report of a 6-year experience with treatment recommendations. J Am Coll Cardiol. 1992;19:1315.
Becker DM, Chamberlain B, Swank R et al. Relationship between corticosteroid exposure and the plasma lipid levels in heart transplant recipients. Am J Med 1988;85:632.
Ballantyne CM. Lipids and cyclosporin A. Transplant Immunol Lett. 1992;8:4.
Rader JI, Calvcrt RJ, Hathcock JN et al. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. 1992;92:77.
Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuck WJ. Cholesterol-lowering therapy after heart transplantation: a 12 month randomized trial. J Heart Lung Transplant. 1995;14:613.
Kobashigawa JA, Murphy FL, Stevenson LW et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation. 1990;82(Suppl. IV):IV–281.
Kohashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621.
Kuo PC, Kirshenbaum JM, Gordon J et al. Lovastatin therapy for hypercholesterolenmia in cardiac transplant recipients. Am J Cardiol. 1989;64:631.
Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc. 1990;264:71.
Reaven P, Wilztum JL, Lovastatin. nicotinic acid and rhabdomyolysis. Ann Intern Med. 1988;109:597.
Muchmore JS, Cooper DKC, Ye Y et al. Prevention of loss of vertebral bone density in heart transplant patients. J Heart Lung Transplant. 1992;11:959.
Sumbrook PN, Kelly PJ, Keogh AM et al. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant. 1994;13:116.
Lee AH, Mull RL, Keenan GF et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96:35.
Shane E, Rivas MC, Silverberg SJ et al. Osteoporosis after cardiac transplantation. Am J Med. 1993;94:257.
Rich CM, Mudge GH, Laffel GL, Leboff MS. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant. 1992;11:950.
Meys E, Bone loss after orthotopic liver transplantation. Am J Med. 1994;97:445.
Grotz WH. Mundinger FA. Gugel B et al. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994;58:912.
Lukert BP, Raisz LG. Glueocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352.
Seeman E, Wanner HW, Offord KP et al. Differential effects of endocrine dysfunction on the axial and appendicular skeleton. J Clin Invest. 1982;69:1302.
Katz IA, Epstein S. Post-transplantation bone disease. J Bone Min Res. 1992;7:123.
Dumoulin G, Hory B, Nguyen NU et al. Lack of evidence of cyclosporin treatment impairs calcium-phosphorus homeostasis and bone remodeling in normocalcemic long-term renal transplant recipients. Transplantation. 1995;59:1690.
Baylink JD. Glucocorticoid-induced osteoporosis. N Engl J Med. 1983;309:306.
Johnston CC Jr, Slemenda CW. Risk assessment: theoretical considerations. Am J Med. 1993;95:2S.
Rivas C, Silverberg SJ, Kim T et al. Osteopenia in cardiac transplant recipients. J Bone Min Res. 1991:6(S1)(abstract 93).
Ross CS. Monitoring L-thyroxine therapy: lessons from the effects of L-thyroxine on bone density (Editorial). Am J Med. 1991;91:1.
Kapsner P, Langsdorf L, Marcus R, Kraemer FB, Hoffman AR. Milk-alkali syndrome in patients treated with calcium carbonate after cardiac transplantation. Arch Intern Med. 1986;146:1965.
Diamond T. McGuigan L. Barbagallo S. Bryant C. Cyclical etidronate plus ergocalciferol prevents glueocorticoid-induced bone loss in postmenopausal women. Am J Med. 1995;98:459.
Chesnut CH, McClung MR, Ensrud KE et al. Alendronate treatment of the post-menopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144.
Gennari C. Effects of deflazacort on bone. In: Peck A, ed. Minimizing the risks of glucocorticoid-induced bone loss. Stamford: GEM Communications; 1993;16.
Isono SS, Woolson ST, Schurman DJ. Total joint arthroplasty for steroid-induced osteonecrosis in cardiac transplant patients. Clin Orthoped. 1987;217:201.
Rozenberg S, Frih L, Lang T et al. Rhcumatological complications in heart transplant recipients. Rev Rheum. 1993;60:11.
Harrington KD, Murray WR, Kountz SL et al. Avascular necrosis of bone after renal transplantation. J Bone J Surg (Am). 1971;53A:203.
Sten PJ. Watts HG. Osteonecrosis after renal transplantation in children. J Bone J Surg (Am). 1979;61:581.
Enright H, Haake R, Weisdorf D et al. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990;89:733.
Feletti C, Di Felice A, Scolari MP, Bonomini V. Glucocorticoids and avascular bone necrosis in renal transplantation. Adv Exp Med Biol. 1984;171:361.
Patton PR, Pfaff WW. Aseptic bone necrosis after renal transplantation. Surgery. 1988;103:63.
Elmstedt E. Avascular bone necrosis in the renal transplant patient: a discriminate analysis of 144 patients. Clin Orthoped. 1981;158:149.
Felson DT, Anderson JJ. A cross-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet. 1987;1:902.
Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporin. Am J Med. 1992;92:141.
Kahl LE, Thompson ME, Griffith BP. Gout in the heart transplant recipient: physiologic puzzle and therapeutic challenge. Am J Med. 1989;87:289.
West C, Carpenter BJ, Hakala TR. The incidence of gout in renal transplant recipients. Am J Kidney Dis. 1987;10:369.
Rodnan GP. Treatment of gout and other forms of crystal-induced arthritis. Bull Rheumatol Dis. 1982;32:43.
Van Thiel DH, Iqbal M, Jain A et al. Gastrointestinal and metabolic problems associated with immunosuppression with either cyclosporin or FK506 in liver transplantation. Transplant Proc. l990;22(Suppl. l):37.
Penn I, Makowski EL, Parenthood in kidney and liver transplant recipients. Transplant Proc. 1981;13:36.
Crosnier J, Broyer M. Treatment of chronic renal failure in children. In: Hamburger J. Crosnier J. Grunfield JP, editors. Nephrology. New York: Wiley: 1979:1361.
Blodgett FM, Burgin L. Tezzoni D, Oribetz D, Talbot NB. Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children. N Engl J Med. 1956;254:636.
Soyka LF, Saxena KM. Alternate-day steroid therapy for nephrotic children. J Am Med Assoc. 1965;192:225.
Potter DE, Holliday MA, Wilson CJ. Salvatierra O. Belzer FO. Alternate-day steroids in children after renal transplantation. Transplant Proc. 1975;7:79.
Debnath SC, Abomelha MS, Jawdat M, Chang R, Al-Khader AA. Ocular side effects of systemic steroid therapy in renal transplant patients. Ann Ophthalmol. 1987;19:435.
Luntz MH, Clinical types of cataracts. In: Duane TD, editor. Duane’s series of ophthalmology, vol.1. Philadelphia, PA: Lippincott. 1980;15.19.
Koranda FC, Dehmel EM, Kahin G, Penn I. Cutaneous complications in immuno-suppressed renal homograft recipients. J Am Med Assoc. 1974;229:419.
Spencer ES, Anderson HK. Clinically evident, non-terminal infections with herpes viruses and the wart virus in immunosuppresed renal allograft recipients. Br Med J. 1970;3:251.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Nelson, D.P., Imes, N.K., Cooper, D.K.C. (1996). Long-Term Management and Late Complications of the Thoracic Organ Transplant Recipient. In: Cooper, D.K.C., Miller, L.W., Patterson, G.A. (eds) The Transplantation and Replacement of Thoracic Organs. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-34287-0_13
Download citation
DOI: https://doi.org/10.1007/978-0-585-34287-0_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-8898-2
Online ISBN: 978-0-585-34287-0
eBook Packages: Springer Book Archive